At a glance
ClinicalIndex Comparison Record- ✓Males 18 years or older
- ✓Informed consent required prior to enrollment
- ✓Imaging-confirmed locally advanced prostate cancer (cT3b-cT4, N0-N1, M0)
- ✓Oligometastatic disease with no visceral metastases and ≤5 bone metastases
- ✕History of hypersensitivity to study drugs
- ✕Prior systemic or localized prostate cancer treatment beyond 28 days of hormonal therapy (LHRHa, NSAA, rezvilutamide)
- ✕Enrollment in other therapeutic clinical studies within 28 days prior to enrollment
- ✕Any approved anticancer therapy within 28 days prior to enrollment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06387056Phase 2RecruitingMonitorUpdated 26mo ago · Completion was 3mo agoAn Exploratory Study of the Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO)
In Brief
A Phase 2 clinical trial evaluating Rezvilutamide, Goserelin Microspheres for Injection, and 4 other interventions for Locally Advanced Prostate Cancer and Oligometastatic Prostate Cancer. Currently recruiting, targeting 40 participants across 1 site.
Signals
Detailed Summary
To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.
Study Details
Timeline
Interventions
240mg by mouth once a day for 24 weeks.
3.6mg by intramuscular injection once 4 weeks for 24 weeks.
70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
60mg by mouth twice a day for 20 weeks.
70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).